We offer a portable, non-invasive sensing technology for early screening of lung cancer and MASH. Our AI-powered technology generates a unique “breath fingerprint” unlike any existing tool. Validated across 10 clinical sites with >80% accuracy and backed by Horizon EU, EIC, the Israeli Innovation Authority, and Google AI, Nanose’s low-cost, scalable solution fills a critical gap in population screening and risk stratification—where current solutions fall short.